Conversely, Bezin et al. found use of GLP-1 receptor agonists was associated with an increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27–1.95) and for medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04–3.05) [57]. Here, GLP1R is linked to thyroid gland carcinoma.